ARQT — Q2 2026 Financial Report Analysis

Overview

Arcutis Biotherapeutics turned a profit in Q2 2026: net income of $15.0 million ($0.11 per diluted share), against a $15.9 million loss a year earlier, on net product revenue up 59% to $129.9 million. All of that revenue comes from one drug, ZORYVE (roflumilast), a steroid-free cream and foam for psoriasis, atopic dermatitis (eczema) and seborrheic dermatitis. Revenue grew far faster than costs: total operating expenses rose 18%, so the company moved from a $14.6 million operating loss to a $16.4 million operating profit. The quarter is cleaner than Q1 2026, when a one-time $10.0 million research milestone pushed Arcutis to an $11.3 million loss.

At a glance

• $129.9M net product revenue, +59% YoY and about +23% on Q1 2026's $105.4M — the launch is still accelerating, not plateauing.
• ZORYVE foam is now $67.4M, 52% of sales, up 72% — the scalp-and-body psoriasis label added in June 2025 is the biggest single growth driver.
• 12.7% operating margin vs. –17.9% a year ago — the first quarter in this comparison where selling costs (63% of revenue, down from 85%) leave room for a profit.

Results table

Source: condensed consolidated statements of operations and MD&A product revenue table, Form 10-Q for the quarter ended June 30, 2026.

What drove revenue

The 10-Q splits sales by product, and every line grew. Its explanations are short but specific:

• Foam (+$28.2M): "greater patient demand for ZORYVE foam for the treatment of seborrheic dermatitis and the commercial launch of ZORYVE foam for plaque psoriasis of the scalp and body in the United States in June 2025." Q2 2025 had almost no psoriasis-foam sales, so part of this 72% is a launch comparison that will be tougher to repeat once the year-ago quarter includes a full period of that indication.
• Cream 0.15% for eczema (+$9.6M, +66%): "primarily driven by greater patient demand." Now in its second year, this is the product facing the biggest market (atopic dermatitis is far more common than psoriasis).
• Cream 0.3% for psoriasis (+$7.7M, +28%): the oldest product (launched August 2022) still grew at a solid rate on demand. An FDA approval in June 2026 extended it down to children aged 2–5, which had no effect on this quarter.
• Cream 0.05% (+$2.9M): the toddler eczema strength, launched October 2025. An application to extend it to infants down to 3 months has an FDA decision date of February 23, 2027.

Sales outside the US (Canada) were under 10% of revenue. The figures are net revenue — what Arcutis keeps after rebates to insurers and pharmacy benefit managers, co-pay assistance to patients and wholesaler fees (together called "gross-to-net" deductions). The 10-Q does not disclose the gross-to-net percentage.

Where the costs went

• Selling, general and administrative (SG&A): $82.1M, +19%. MD&A attributes the rise mainly to "increases in compensation and employee benefit related expenses of $9.5 million" and sales and marketing up $1.9 million, including "the expansion of our dermatology sales force." Arcutis ended its primary-care promotion deal with Kowa in January 2026 and now covers primary care and pediatricians with its own team; Kowa commissions fell, but staffing rose. Because revenue grew three times faster, SG&A fell from 85% to 63% of revenue — this operating leverage (fixed-ish costs spread over more sales) is the whole story of the swing to profit.
• R&D: $20.4M, +5%. Higher headcount and medical education, partly offset by lower spending as the INTEGUMENT-INFANT trial winds down. Management expects R&D to increase as the ARQ-234 biologic for eczema (Phase 1a/1b, first patient dosed March 2026) progresses.
• Cost of sales: $10.9M, up $3.4M on volume and royalties; gross margin stayed above 90%, typical of a topical drug.

What the headline numbers hide

• Q1's milestone is why the half-year profit looks small. H1 2026 net income was only $3.7M because Q1 carried a $10.0M R&D expense owed to the former owners of Ducentis (the company Arcutis bought for ARQ-234) when the first trial patient was dosed. Arcutis paid $0.8M in cash and issued $9.2M of interest-free promissory notes due 12 months from April 2026 (callable by holders after seven months). That cash still has to go out — as early as November 2026 if holders call the notes, and by April 2027 at the latest — and $386.0M of further Ducentis milestones remain possible if the program advances.
• Cash generation is real but modest, and partly timing. H1 operating cash flow was +$14.9M vs. a $30.1M outflow a year ago. But it was helped by the unpaid Ducentis notes still sitting in accrued liabilities, and by $23.5M of stock-based compensation, a non-cash cost (paid in shares, which dilutes holders instead). Q2 alone included $13.1M of stock compensation, close to the full $16.4M operating profit, so the profit is a GAAP profit but owners are still paying for part of it through dilution: diluted share count rose to 135.9M from 127.0M.
• Rebate liabilities are growing quickly. Accrued sales deductions (rebates and fees owed but not yet paid) rose to $107.8M from $78.3M at December 31, and prepaid co-pay assistance and rebates nearly doubled to $16.8M from $9.5M. Both are consistent with higher volume, but they are estimates that a payer contract change could revise.
• Inventory jumped 72% in six months (to $38.9M from $22.6M), but most of it is raw materials ($15.9M vs. $5.0M); finished goods rose only 13%. That looks like supply build rather than unsold product stuck in the channel. Trade receivables grew 6% since December, slower than sales.
• No buyback or tax effect: the EPS swing comes entirely from operations; tax was a negligible $0.1M.

Takeaway: Arcutis's profit came from operating leverage, not cost cuts — revenue grew 59% while SG&A grew 19% — so it should hold as long as ZORYVE demand keeps compounding. The catch is quality: about four-fifths of Q2's operating profit equals non-cash stock compensation, and half-year cash flow was flattered by a $9.2M milestone still to be paid.

Balance sheet and debt

Cash, cash equivalents, restricted cash and marketable securities were $238.9M at June 30, up from $221.3M at year-end. Debt is $100.0M under the SLR term loan (9.57% floating rate at June 30, maturing August 2029), plus a $6.95M final fee due January 4, 2027. Neither of the optional $50M tranche C loans was drawn before they expired, and the company says it was in compliance with all covenants, including a minimum net-revenue test. Management states it does "not anticipate the need to obtain funds through financings or other sources to support our current planned operations" and that existing resources cover at least 12 months.

Outlook

The 10-Q gives no revenue or profit guidance. Management says both SG&A and R&D will keep rising — SG&A as commercialization continues and R&D for ARQ-234 and ZORYVE label expansions. Our read: with sequential revenue growth of about 23% from Q1 to Q2 and cost growth well below that, quarterly profitability looks sustainable if the eczema creams keep gaining share. Near-term drags are the ~$16M of known cash payments (Ducentis notes plus the loan's final fee) due between late 2026 and April 2027, and the foam's growth rate, which will slow from 72% as the June 2025 psoriasis launch moves into the year-ago comparison. Things to watch in Q3: whether cream 0.15% eczema revenue keeps rising faster than the foam, and whether accrued sales deductions keep growing faster than net revenue (a sign of deeper discounts to win insurance coverage).